Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Rating of “Buy” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been given an average rating of “Buy” by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and three have issued a strong buy recommendation on the company.

A number of research analysts recently issued reports on BAYRY shares. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Finally, UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th.

Bayer Aktiengesellschaft Trading Down 1.7%

OTCMKTS:BAYRY opened at $10.92 on Wednesday. The stock’s 50 day moving average price is $11.27 and its 200 day moving average price is $11.17. The company has a market capitalization of $42.92 billion, a PE ratio of -17.06, a P/E/G ratio of 3.54 and a beta of 0.62. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. Bayer Aktiengesellschaft has a 52-week low of $6.97 and a 52-week high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.